Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
06 août 2024 16h05 HE
|
Vaxcyte, Inc.
-- VAX-31 Adult Phase 1/2 Study Topline Safety, Tolerability and Immunogenicity Data Expected in September 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Results, Vaxcyte to Advance VAX-24 or...
Vaxcyte Appoints John Furey to Board of Directors
02 juil. 2024 08h30 HE
|
Vaxcyte, Inc.
Vaxcyte appoints John Furey to Board of Directors.
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
08 mai 2024 16h05 HE
|
Vaxcyte, Inc.
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout,...
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
02 avr. 2024 16h05 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
04 mars 2024 08h30 HE
|
Vaxcyte, Inc.
-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the First Quarter of 2025, Followed by Topline Data from Booster Dose...
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
27 févr. 2024 16h01 HE
|
Vaxcyte, Inc.
-- VAX-31 Adult Program Phase 1/2 Study Enrollment Complete; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Completed Successful VAX-24 Phase 2 Adult...
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
15 févr. 2024 16h05 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
02 févr. 2024 18h39 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
01 févr. 2024 16h05 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Vaxcyte Announces Pricing of $750 Million Public Offering
30 janv. 2024 23h37 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...